2022 in Review: Best in MBC with Dr. Erika Hamilton
Quality of Life, Clinical Research, Novel Treatments, Challenges and Barriers, Medical Community, Clinical Trials Process, Obstacles to Better Outcomes Our MBClife Quality of Life, Clinical Research, Novel Treatments, Challenges and Barriers, Medical Community, Clinical Trials Process, Obstacles to Better Outcomes Our MBClife

2022 in Review: Best in MBC with Dr. Erika Hamilton

Welcome to the first Road to A Cure episode of Season 6. Our guest is the incomparable Dr. Erika Hamilton, a breast oncologist and researcher who, as she says herself, doesn’t shy away from difficult questions. In this episode, we get a review—subtype by subtype—of the biggest news over the past 15 months. Of course, we also talk about what is on the horizon in MBC.

Read More
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife Novel Treatments, Clinical Research, Medical Community, Entities of Cancer, Diagnosis and Treatment, Difficult to Treat, Updates from Conferences Our MBClife

ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.

Read More
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
Entities of Cancer, Difficult to Treat, Novel Treatments, Medical Community, Clinical Research, Updates from Conferences Our MBClife Entities of Cancer, Difficult to Treat, Novel Treatments, Medical Community, Clinical Research, Updates from Conferences Our MBClife

Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?

MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.

Read More